All In Biotech

Drug Trial Radar · NCT06641180

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age.

Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,180

Actual

Start

Nov 4, 2024

Primary completion

Jan 28, 2025

Study completion Jun 24, 2025

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age.

Conditions

  • Influenza

Interventions

  • High-Dose trivalent influenza vaccine (Split virion, Inactivated)Biological

    Liquid suspension for intramuscular injection

  • Standard-dose trivalent influenza vaccine (Split virion, Inactivated)Biological

    Liquid suspension for intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean titers (GMTs) against influenza vaccine antibodies (Ab)Time frame: Day 1 and Day 29
  2. Percentage of participants with seroconversion for influenza vaccine antibodiesTime frame: Day 29

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel CNS- Site Number : 8400005

    Los Alamitos, California

  • Alliance for Multispeciality Research - Fort Myers- Site Number : 8400019

    Fort Myers, Florida

  • Research Centers of America - Hollywood- Site Number : 8400010

    Hollywood, Florida

  • IACT Health - Columbus - Talbotton Road- Site Number : 8400011

    Columbus, Georgia

  • Cenexel IRA - iResearch Atlanta- Site Number : 8400007

    Decatur, Georgia

  • The Hope Clinic of Emory Vaccine Center- Site Number : 8400017

    Decatur, Georgia

  • Centricity Research - Rincon- Site Number : 8400012

    Rincon, Georgia

  • Cenexel IRS - iResearch Savannah- Site Number : 8400008

    Savannah, Georgia

  • Alliance for Multispeciality Research - Newton- Site Number : 8400003

    Newton, Kansas

  • Alliance for Multispeciality Research - Lexington- Site Number : 8400002

    Lexington, Kentucky

  • CBH Health - Gaithersburg- Site Number : 8400004

    Gaithersburg, Maryland

  • Hassman Research Institute - Berlin- Site Number : 8400006

    Berlin, New Jersey

  • Centricity Morehead- Site Number : 8400014

    Morehead City, North Carolina

  • Centricity New Bern- Site Number : 8400015

    New Bern, North Carolina

  • Aventiv Research Columbus- Site Number : 8400016

    Columbus, Ohio

  • Kaiser Permanente Center for Health Research- Site Number : 8400018

    Portland, Oregon

  • Alliance for Multispecialty Research - Volunteer Research Group- Site Number : 8400001

    Knoxville, Tennessee

  • JBR Clinical Research- Site Number : 8400009

    Salt Lake City, Utah

  • Centricity Research - Suffolk Primary Care - Centricity - PPDS- Site Number : 8400013

    Suffolk, Virginia

  • Kaiser Permanente Washington- Site Number : 8400024

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.